Previous 10 | Next 10 |
Shares of KalVista Pharmaceuticals (NASDAQ: KALV) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks. KalVista's study showed that 15% of the pat...
After a surge of 150% in premarket hours, KalVista (KALV) has continued the momentum to close ~114.6% higher today on above-average volume after the company announced the positive Phase 2 data for KVD900 as an oral on-demand therapy for hereditary angioedema (‘HAE’) at...
KalVista Pharma (KALV) announces that it intends to offer and sell 4.5M shares in an underwritten public offering.KalVista also intends to grant the underwriters a 30-day option to purchase up to an additional 675K shares.The company said it will look to use the net proceeds from the of...
Gainers: Applied UV (AUVI) +367%.Comstock Holding Companies (CHCI) +125%.KalVista Pharmaceuticals (KALV) +112%.Veru (VERU) +60%.Heat Biologics (HTBX) +58%.SemiLEDs (LEDS) +45%.U.S. Well Services (USWS) +41%.Tilray (TLRY) +41%.Eastside Distilling (EAST) +40%.FSD Pharma (HUGE) +35%.Lo...
KalVista Pharma shares (KALV) skyrocketed nearly 150% during premarket trading after the company announced positive topline data from a phase 2 clinical trial of KVD900 as an oral on-demand treatment for hereditary angioedema ((HAE)) attacks.KVD900 Phase 2 was a randomized, dou...
KalVista Pharmaceuticals (KALV) +207% on reporting positive results for KVD900.Comstock Holding Companies (CHCI) +163%.Applied UV (AUVI) +88% after acquiring Airocide Technology Platform.Heat Biologics (HTBX) +47% on announcing positive interim survival data from ongoing HS-110...
– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – – Conference Call to Discuss Trial Results Today at 8:30 a.m. ET ȁ...
Pharming Group N.V. has filed to offer an estimated $10.9 million in Registered Holder shares in a U.S. offering. The firm is commercializing a treatment for hereditary angioedema and developing a treatment for pneumonia brought on by the Covid-19 virus. The firm is generating rev...
– Chair and board member Michael Wolf Jensen will not stand for re-election at 2021 Annual General Meeting – – Board of Directors intends to appoint Dr. Albert Cha to serve as Chair after 2021 AGM – COPENHAGEN, Denmark, Dec. 14, 2020 (GL...
KalVista Pharmaceticals (KALV): Q2 GAAP EPS of -$0.58 beats by $0.09.Cash, cash equivalents and marketable securities were $55.9 million as of October 31, 2020, compared to $67.7 million as of April 30, 2020.Press Release For further details see: KalVista Pharmaceticals EPS beats by $0....
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...